Clinical trial
Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV…
NCT00147121 · Haruhiko Fukuda, Other · Completed
Key facts
| NCT number | NCT00147121 |
|---|---|
| Title | Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) |
| Official title | Rituximab + Standard CHOP (R･S-CHOP) vs Rituximab+ Bi-weekly CHOP (R･Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203) |
| Lead sponsor | Haruhiko Fukuda, Other |
| Collaborators | Ministry of Health, Labour and Welfare, Japan |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, B-Cell |
| Intervention type | Drug |
| Interventions | Rituximab + Standard CHOP, Rituximab + Bi-weekly CHOP |
| Enrollment | 300 |
| Start date | Sep 1, 2002 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Sep 7, 2005 |
| Last update posted | Sep 22, 2016 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: